A Multicenter, Open-Label Phase 1 Study of HER3-DXd in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer
Latest Information Update: 30 May 2024
At a glance
- Drugs Patritumab Deruxtecan (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 13 May 2024 Planned number of patients changed from 264 to 309.
- 13 May 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
- 13 May 2024 Planned primary completion date changed from 31 Dec 2021 to 31 Mar 2026.